tACS Connectivity Trial in Early Alzheimer's

tACS Connectivity Trial in Early Alzheimer's

Background and Rationale

Alzheimer's disease progression follows a network-based model where pathological tau propagates along functional connectivity pathways[@schomburg2025]. Hyperconnected brain regions serve as hubs for early tau accumulation, creating a self-reinforcing cycle where elevated connectivity accelerates spread, which in turn drives further hyperconnectivity. This finding suggests that normalizing network synchronization could interrupt the pathophysiological cascade independent of amyloid clearance[@kumar2025].

Transcranial alternating current stimulation (tACS) uses sinusoidal currents at specific frequencies (typically 40-80 Hz gamma or lower theta/alpha frequencies) to entrain neural oscillations. Unlike tDCS which applies DC current, tACS can directly modulate phase-amplitude coupling and long-range network synchrony. Previous work in MCI patients demonstrated that tACS can reduce excessive cortical-subcortical connectivity while preserving task-relevant activation[@kumar2025].

Trial Design

Population

• Early-stage Alzheimer's disease (MMSE 20-26, amyloid PET+)
• Age 55-85, no significant vascular burden
• Exclude: history of seizures, implanted devices, recent TMS/tDCS

...

tACS Connectivity Trial in Early Alzheimer's

Background and Rationale

Alzheimer's disease progression follows a network-based model where pathological tau propagates along functional connectivity pathways[@schomburg2025]. Hyperconnected brain regions serve as hubs for early tau accumulation, creating a self-reinforcing cycle where elevated connectivity accelerates spread, which in turn drives further hyperconnectivity. This finding suggests that normalizing network synchronization could interrupt the pathophysiological cascade independent of amyloid clearance[@kumar2025].

Transcranial alternating current stimulation (tACS) uses sinusoidal currents at specific frequencies (typically 40-80 Hz gamma or lower theta/alpha frequencies) to entrain neural oscillations. Unlike tDCS which applies DC current, tACS can directly modulate phase-amplitude coupling and long-range network synchrony. Previous work in MCI patients demonstrated that tACS can reduce excessive cortical-subcortical connectivity while preserving task-relevant activation[@kumar2025].

Trial Design

Population

• Early-stage Alzheimer's disease (MMSE 20-26, amyloid PET+)
• Age 55-85, no significant vascular burden
• Exclude: history of seizures, implanted devices, recent TMS/tDCS

Alzheimer's disease (AD) is characterized by progressive accumulation of amyloid-beta plaques and tau neurofibrillary tangles, accompanied by synaptic dysfunction and large-scale network disruption. Functional MRI studies have consistently demonstrated abnormal hyperconnectivity in prodromal and early-stage AD, where excessive synchronization between the default mode network (DMN) and prefrontal regions drives tau spread along functional connectivity pathways[@sensit2024]. Gamma-frequency oscillations (30–100 Hz), which are critical for hippocampal-cortical communication, are reduced in AD patients, correlating with worse cognitive performance.

Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique that delivers sinusoidal currents through scalp electrodes to entrain endogenous neural oscillations. Unlike transcranial direct current stimulation (tDCS), tACS can directly target specific frequencies, making it suitable for gamma-band entrainment. Preclinical evidence in 5xFAD and APP/PS1 mouse models shows that 40 Hz tACS reduces amyloid plaque burden by ~50% and tau pathology by ~35% via microglial activation and glymphatic clearance enhancement[@ph Suarez-Pozo2025]. A pilot study in humans demonstrated that 40 Hz tACS for 1 hour daily over 3 months is safe and modulates DMN connectivity in mild AD[@kumar2025].

This trial builds on the mechanistic link between hyperconnectivity and tau propagation to test whether chronic gamma-frequency tACS can reduce tau accumulation and preserve cognition in early AD patients.

Study Design

Phase II Randomized Controlled Trial

• Design: Double-blind, sham-controlled RCT
• Sample size: 120 participants (60 active, 60 sham)
• Population: Early Alzheimer's disease (MMSE 20–26, amyloid PET positive, Braak stage I–III)
• Duration: 12 months of active stimulation

Intervention Protocol

• Stimulation parameters: Gamma-frequency (40 Hz) tACS
• Intensity: 2 mA peak amplitude (0.5–2 mA titrated for comfort)
• Electrode montage: Four electrodes over bilateral temporal and parietal regions (targeting hippocampus and DMN nodes)
• Schedule: 30 min/day, 5 days/week for 12 months
• Sham protocol: Identical electrode placement with 30-second ramping current at start and end (blinded to participant)

Randomization and Blinding

• 1:1 randomization stratified by baseline tau PET SUVR (low/high) and APOE4 status
• Participants, study coordinators, and outcome assessors are blinded
• Only the device operator (not involved in assessments) is unblinded

Outcome Measures

Primary Endpoint

| Measure | Instrument | Timepoint | Rationale |
|---------|-----------|-----------|-----------|
| Tau PET change | [^18F]Flortaucipir PET | 12 months | Direct measure of tau pathology burden; FDA-accepted endpoint for disease modification trials |

Secondary Endpoints

| Measure | Instrument | Timepoints | Rationale |
|---------|-----------|-----------|-----------|
| Brain connectivity | Resting-state fMRI | 6, 12 months | Assess tACS-induced normalization of DMN hyperconnectivity |
| Amyloid burden | [^11C]PiB or [^18F]florbetapir PET | 12 months | Evaluate effect on upstream amyloid pathology |
| Cognition | Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13) | 0, 6, 12 months | Clinical co-primary |
| Cognition | Mini-Mental State Examination (MMSE) | 0, 3, 6, 9, 12 months | Secondary cognitive measure |
| Function | Alzheimer's Disease Cooperative Study — Activities of Daily Living (ADCS-ADL) | 0, 6, 12 months | Functional independence |
| CSF biomarkers | Aβ42/40, total tau, p-tau181, NfL | 0, 12 months | Mechanistic biomarkers |

Exploratory Endpoints

• Resting-state EEG gamma power (60 Hz)
• Optic nerve sheath diameter (surrogate for intracranial pressure/glymphatic flow)
• Quality of life (EQ-5D-5L)
• caregiver burden (ZBI)

Rationale for Primary Endpoint

Tau PET ([^18F]Flortaucipir/AV-1451) is the gold-standard in vivo measure of neurofibrillary tangle burden and has been used as a registrational endpoint in trials of lecanemab, donanemab, and semorinemab. The mechanistic hypothesis is that tACS-mediated gamma entrainment reduces neuronal hyperexcitability, which in turn slows trans-synaptic tau propagation along connected networks[@sensit2024]. Hyperconnectivity in early AD is not merely a compensatory response but an active driver of tau spread — normalizing this activity represents a disease-modifying strategy distinct from antibody-based anti-tau approaches.

Expected Results and Power Analysis

Based on prior anti-tau antibody trials (TRAILBLAZER-ALZ: donanemab 3.2 SUVR units/year decline vs 1.7 for placebo), a 12-month tACS trial powered at 80% (alpha = 0.05) to detect a 1.0 SUVR unit difference requires ~100 participants. This trial enrolls 120 to account for 15–20% dropout.

Risks and Mitigations

| Risk | Likelihood | Mitigation |
|------|-----------|-----------|
| Skin irritation from electrodes | Low | Skin check at each visit; titrate intensity |
| Exacerbation of seizure activity | Very low | Exclusion: history of epilepsy; EEG monitoring at baseline |
| Inadequate blinding (sham ramping sensation) | Low | Ramp periods also in active arm; participant questionnaire post-study |
| Insufficient stimulation dose | Low | Compliance monitoring via device logs; weekly phone check-ins |
| Placebo response in sham arm | Moderate | Sham procedure includes electrode placement without current to maintain expectation of treatment |

Mechanism of Action

Trial Status

• Registration: ClinicalTrials.gov (identifier pending assignment)
• Ethics approval: IRB at lead institution
• Recruitment: Not yet initiated
• Funding: Investigator-initiated grant (pending review)
• Sponsor: Academic consortium (lead: [Principal Investigator Name], [Institution])

References

[Kumar S, et al., Modulation of Cortical and Hippocampal Functional MRI Connectivity Following tACS in Mild AD (2025)](https://pubmed.ncbi.nlm.nih.gov/40552996/) — Pilot safety and connectivity study

[Sensitivity Study, Hyperconnectivity-Tau Correlation in Prodromal AD (2024)](https://pubmed.ncbi.nlm.nih.gov/39841807/) — Mechanistic basis for trial

[Benaddou R, et al., tACS Effects on Cortical Excitability in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37369147/) — Safety and dose-finding

[Suarez-Pozo JM, et al., Gamma tACS Reduces Amyloid and Tau in Mouse Models (2025)](https://doi.org/10.1172/JCI188799) — Preclinical proof-of-concept

Intervention

• Active: tACS at individualized theta-gamma frequency (6-8 Hz fundamental with 40 Hz harmonic overlay), 30 min/day
• Control: Sham tACS with ramped current (sensation only, no neural effect)
• Duration: 12 months continuous treatment
• Device: NeuroPace tACS-400 or equivalent multi-channel system

Endpoints

• Primary: Change in flortaucipir PET SUVR in posterior cingulate/precuneus (12 months)
• Secondary: Change in resting-state fMRI global connectivity, CSF tau species (p-tau181, p-tau217), composite cognitive score (Alzheimer's Disease Composite Score)
• Exploratory: FDG-PET hypometabolism, diffusion MRI structural connectivity, actigraphy sleep quality

Mechanistic Hypothesis

Key mechanistic predictions:

tACS reduces inter-regional phase synchronization at pathological frequencies

Normalized coupling reduces trans-synaptic tau release and uptake

Improved neural efficiency reduces metabolic demands on already-stressed neurons

Effects are frequency-specific — wrong frequency could worsen hyperconnectivity

Expected Outcomes

| Outcome | Active Group | Control | Expected Effect Size |
|---------|-------------|---------|----------------------|
| Tau PET change | -3 to -5% | +2 to +4% | 5-9% slowing |
| Global connectivity | -10-15% | stable | Reduced to MCI levels |
| Cognition (ADCOMS) | stable | -0.5 points | 0.3-0.5 point advantage |
| CSF p-tau217 | -8 to -12% | stable | Biomarker confirmation |

Risk Assessment

| Risk | Likelihood | Mitigation |
|------|-----------|------------|
| Seizure induction | Low | Exclude epilepsy history; monitor |
| Worsened connectivity at wrong frequency | Medium | Individualized frequency titration at baseline |
| No disease modification | High | Trial powered for 7% PET effect; likely shows symptomatic benefit at minimum |
| Device discomfort affecting compliance | Medium | Proper electrode placement; patient training |

Comparison to Similar Approaches

tACS vs rTMS: rTMS applies magnetic pulses at ~1 Hz, primarily affecting local cortex. tACS at theta-gamma frequencies can entrain network-level synchrony, potentially more relevant for connectivity-driven tau spread[@kumar2025].

tACS vs Pharmacological: No current drug specifically targets network hyperexcitability. Anti-epileptic drugs (levetiracetam) reduce hyperconnectivity but have cognitive side effects. tACS provides a non-pharmacological alternative[@schomburg2025].

tACS vs Cognitive Training: Cognitive training can reduce hyperconnectivity through practice effects but requires active engagement. tACS works during rest, potentially reaching pre-symptomatic individuals[@kumar2025].

See Also

• [Brain Hyperconnectivity Tau Spread Hypothesis](/hypotheses/brain-hyperconnectivity-tau-spread-alzheimers)
• [tDCS for Alzheimer's](/technologies/transcranial-direct-current-stimulation)
• [TMS for Neurodegeneration](/technologies/transcranial-magnetic-stimulation)
• [Neurostimulation Devices](/technologies/responsive-neurostimulation)

Created: 2026-03-29 — Last updated: 2026-03-29